Uncategorized
J.P. Morgan Healthcare Conference 2023 Transcript
Transcription may have some errors – apologize in advance Paul Edick – I would remind everyone to pay attention to our forward looking statements. Investing is always a risk. We’ll start out with an overview of the company. Xeris has a very diversified revenue base. We have three marketed assets, all growing record level. I’ll…
Q1 2022 Earning Call Audio & Transcription
Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Updated with Seeking Alpha transcript: Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30…
Q4 2021 Earning Call Audio & Transcription
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey – SVP, IR and Corporate Communications Paul Edick – Chairman and CEO Steve Pieper – CFO Conference Call Participants Roanna Ruiz – SVB Leerink Vamil Divan – Mizuho Securities David Amsellem – Piper Sandler Operator Hello everyone….
2021 Q3 Earnings Call Recording
Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Edit: Transcription has been updated using Seeking Alpha | Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10,…
XERS – Bull Case Shows 217% Upside while Bear Case Shows 42% Upside
The tl;dr is that a bull case evaluation for XERS shows an upside of 217% with PT $14.21 and a bear case evaluation shows an upside of 42% with PT $6.38. Note that this does not factor in the possibility of a short squeeze which could increase the price past its fundamental value. Given the…
An Undeserved Valuation: Xeris Pharmaceuticals
Source: Fortune Team | Jan 23 | Updated: Jan 24 | Blatantly undervalued and under-followed, Xeris has the potential to shine significantly in 2021, ascending as a true Fortune Alert( alerted initially in $2s). Take a look at our thoughts in a nutshell: Overview Xeris is a specialty pharmaceutical company that offers bold, innovative formulation technologies:…
- 1
- 2